SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics total assets
Total assets on the balance sheet at the end of each period.
SAB Biotherapeutics's total assets was $235.64M at Sep 30, 2026. For fiscal 2025 it was $172.81M, up 291.0% from the year before. The highest annual figure on record is $172.81M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.81M | +291.0% |
| FY2024 | Dec 31, 2024 | $44.20M | -47.3% |
| FY2023 | Dec 31, 2023 | $83.94M | +64.9% |
| FY2022 | Dec 31, 2022 | $50.90M | -37.3% |
| FY2021 | Dec 31, 2021 | $81.14M | +43.5% |
| FY2020 | Dec 31, 2020 | $56.54M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $235.64M | +28.5% |
| Q2 FY2026 | Jun 30, 2026 | $238.21M | +690.6% |
| Q1 FY2026 | Mar 31, 2026 | $248.47M | +551.8% |
| Q4 FY2025 | Dec 31, 2025 | $172.81M | +291.0% |
| Q3 FY2025 | Sep 30, 2025 | $183.45M | +241.0% |
| Q2 FY2025 | Jun 30, 2025 | $30.13M | -51.3% |
| Q1 FY2025 | Mar 31, 2025 | $38.12M | -46.6% |
| Q4 FY2024 | Dec 31, 2024 | $44.20M | -47.3% |
| Q3 FY2024 | Sep 30, 2024 | $53.80M | +89.9% |
| Q2 FY2024 | Jun 30, 2024 | $61.89M | +74.6% |
| Q1 FY2024 | Mar 31, 2024 | $71.37M | +67.3% |
| Q4 FY2023 | Dec 31, 2023 | $83.94M | +64.9% |
| Q3 FY2023 | Sep 30, 2023 | $28.34M | -46.0% |
| Q2 FY2023 | Jun 30, 2023 | $35.44M | -40.3% |
| Q1 FY2023 | Mar 31, 2023 | $42.67M | -37.7% |
| Q4 FY2022 | Dec 31, 2022 | $50.90M | -37.3% |
| Q3 FY2022 | Sep 30, 2022 | $52.51M | -55.1% |
| Q2 FY2022 | Jun 30, 2022 | $59.41M | -49.3% |
| Q1 FY2022 | Mar 31, 2022 | $68.49M | -41.6% |
| Q4 FY2021 | Dec 31, 2021 | $81.14M | +43.5% |
| Q3 FY2021 | Sep 30, 2021 | $116.93M | – |
| Q2 FY2021 | Jun 30, 2021 | $117.09M | – |
| Q1 FY2021 | Mar 31, 2021 | $117.27M | – |
| Q4 FY2020 | Dec 31, 2020 | $56.54M | – |
See a number that looks wrong?